Antitumor effect and toxicity of free rhodium (II) citrate and rhodium (II) citrate-loaded maghemite nanoparticles in mice bearing breast cancer

Journal of Nanobiotechnology

Volumn 11, Issue 1, 2013, Pages

  Carneiro, Marcella Lemos Brettas ^a   Peixoto, Raphael C A ^a   Joanitti, Graziela A ^a   Oliveira, Ricardo G S ^a   Telles, Luis A M ^a   Miranda Vilela, Ana L ^a   Bocca, Anamélia L ^a   Vianna, Leonora M S ^b   da Silva, Izabel C R ^c   de Souza, Aparecido R ^d   Lacava, Zulmira G M ^a   Báo, Sônia N ^a  

^a INSTITUTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c Faculdade LS   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI-TUMOR ACTIVITIES; ANTITUMOR EFFECT; BALB/C MICE; BONE MARROW CELLS; BREAST CANCER; BREAST CANCER CELLS; BREAST CARCINOMA CELLS; CELL CYCLE; DNA FRAGMENTATION; EXPERIMENTAL GROUPS; GROWTH INHIBITION; IN-VITRO; MAGHEMITE NANOPARTICLE; MAGHEMITES; NANO-CARRIERS; ORTHOTOPIC; SERUM LEVELS; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; SYSTEMIC TOXICITIES; THERAPEUTIC APPLICATION; THERAPEUTIC EFFICACY; TUMOR TISSUES; TUMOR VOLUMES;

AMINO ACIDS; BODY FLUIDS; CELL CULTURE; CELL PROLIFERATION; CELLS; CHEMOTHERAPY; DISEASES; ENZYME INHIBITION; HISTOLOGY; IRON ORES; MAGNETIC FLUIDS; MAMMALS; NANOPARTICLES; RHODIUM; SUPERPARAMAGNETISM; TOXICITY; TUMORS;

RHODIUM COMPOUNDS;

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; CREATININE; FERRIC OXIDE; IRON; KI 67 ANTIGEN; NANOCARRIER; RHODIUM CITRATE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DNA FRAGMENTATION; DRUG FORMULATION; FEMALE; GENOTOXICITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IRON BLOOD LEVEL; MITOSIS; MOUSE; NONHUMAN; TUMOR DIFFERENTIATION;

ALANINE TRANSAMINASE; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CITRIC ACID; CREATININE; DNA FRAGMENTATION; FEMALE; FERRIC COMPOUNDS; HUMANS; IMMUNOHISTOCHEMISTRY; IRON; KI-67 ANTIGEN; KIDNEY; LIVER; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED BALB C; RHODIUM; ULTRAVIOLET RAYS;

MUS;

EID: 84873715220     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-11-4     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 61:69-90.
2. Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Blood Substit Immobil Biotechnol 38:230-249.
3. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004, 56:1649-1659. 10.1016/j.addr.2004.02.014, 15350294.
4. Babincova M, Babinec P. Magnetic drug delivery and targeting: principles and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009, 153:243-250. 10.5507/bp.2009.042, 20208962.
5. Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14:67-77.
6. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31:3694-3706.
7. Tran LA, Wilson LJ. Nanomedicine: making controllable magnetic drug delivery possible for the treatment of breast cancer. Breast Cancer Res 13:303.
8. Xu C, Sun S. Superparamagnetic nanoparticles as targeted probes for diagnostic and therapeutic applications. Dalton Trans 2009, 5583-5591.
9. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine 2005, 1:22-30. 10.1016/j.nano.2004.11.009, 17292054.
10. Sarfati G, Dvir T, Elkabets M, Apte RN, Cohen S. Targeting of polymeric nanoparticles to lung metastases by surface-attachment of YIGSR peptide from laminin. Biomaterials 32:152-161.
11. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131-135.
12. Kong SD, Zhang W, Lee JH, Brammer K, Lal R, Karin M, Jin S. Magnetically Vectored Nanocapsules for Tumor Penetration and Remotely Switchable On-Demand Drug Release. Nano Lett Nano Lett,
13. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021. 10.1016/j.biomaterials.2004.10.012, 15626447.
14. Monge-Fuentes V, Garcia MP, Tavares MC, Valois CR, Lima EC, Teixeira DS, Morais PC, Tomaz C, Azevedo RB. Biodistribution and biocompatibility of DMSA-stabilized maghemite magnetic nanoparticles in nonhuman primates (Cebus spp.). Nanomedicine (Lond) 6:1529-1544.
15. Asadishad B, Vossoughi M, Alamzadeh I. In vitro release behavior and cytotoxicity of doxorubicin-loaded gold nanoparticles in cancerous cells. Biotechnol Lett 2010, 32:649-654. 10.1007/s10529-010-0208-x, 20131082.
16. Ling Y, Wei K, Luo Y, Gao X, Zhong S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. Biomaterials 32:7139-7150.
17. Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 2005, 21:8858-8864. 10.1021/la0503451, 16142971.
18. Dreaden EC, Mwakwari SC, Sodji QH, Oyelere AK, El-Sayed MA. Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment. Bioconjug Chem 2009, 20:2247-2253. 10.1021/bc9002212, 2839930, 19919059.
19. Kettering M, Zorn H, Bremer-Streck S, Oehring H, Zeisberger M, Bergemann C, Hergt R, Halbhuber KJ, Kaiser WA, Hilger I. Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications. Phys Med Biol 2009, 54:5109-5121. 10.1088/0031-9155/54/17/003, 19661569.
20. Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol 2003, 7:481-489. 10.1016/S1367-5931(03)00081-4, 12941423.
21. Katsaros N, Anagnostopoulou A. Rhodium and its compounds as potential agents in cancer treatment. Crit Rev Oncol Hematol 2002, 42:297-308. 10.1016/S1040-8428(01)00222-0, 12050021.
22. Zyngier S, Kimura E, Najjar R. Antitumor effects of rhodium (II) citrate in mice bearing Ehrlich tumors. Braz J Med Biol Res 1989, 22:397-401.
23. Carneiro ML, Nunes ES, Peixoto RC, Oliveira RG, Lourenco LH, da Silva IC, Simioni AR, Tedesco AC, de Souza AR, Lacava ZG, Bao SN. Free rhodium (II) citrate and rhodium (II)citrate magnetic carriers as potential strategies for breast cancer therapy. J Nanobiotechnology 9:11.
24. Becker M, Moritz A, Giger U. Comparative clinical study of canine and feline total blood cell count results with seven in-clinic and two commercial laboratory hematology analyzers. Vet Clin Pathol 2008, 37:373-384. 10.1111/j.1939-165X.2008.00085.x, 2712287, 19055571.
25. Miras-Parra FJ, Parra-Ruiz J, Gomez-Morales M, Gomez-Jimenez FJ, de la Higuera-Torres-Puchol J. Inflammatory pseudotumor of lymph nodes with focal infiltration in liver and spleen. Dig Dis Sci 2003, 48:2003-2004. 10.1023/A:1026182607257, 14627348.
26. Parchment RE. Oncology clinical trials and in vitro prediction models for xenobiotic toxicology. Develop. Animal Vet Sci 2000, 31:693-708.
27. Guedes MHA, Guedes MEA, Morais PC, Da Silva MF, Santos TS, Alves JP, Bertelli CE, Azevedo RB, Lacava ZGM. Proposal of a magnetohyperthermia system: preliminary biological tests. J Magn Magn Mater 2004, 272â€" 276, Part 3:2406-2407. 3480196, 23105167.
28. Estevanato L, Cintra D, Baldini N, Portilho F, Barbosa L, Martins O, Lacava B, Miranda-Vilela AL, Tedesco AC, Bao S. Preliminary biocompatibility investigation of magnetic albumin nanosphere designed as a potential versatile drug delivery system. Int J Nanomedicine 6:1709-1717.
29. Sadeghiani N, Guedes MHA, Oliveira DM, Tedesco AC, Lima ECO, Azevedo RB, Morais PC, Lacava ZGM. Effects of Magnetic Field and Magnetoliposomes on Mice: Cytotoxicity and Genotoxicity Tests. Magnetics, IEEE Transactions on 2006, 42:3605-3607.
30. Lacava ZGM, Azevedo RB, Martins EV, Lavava LM, Freitas MLL, Garcia VAP. Biological effect of magnetic fluids: toxicity studies. J Magn Magn Mater 1999, 201:431-434.
31. Morais PC, Santos RL, Pimenta ACM, AR B, LEC D. Preparation and characterization of ultra-stable biocompatible magnetic fluids using citrate-coated cobalt ferrite nanoparticles. Thin Solid Films 2006, 515:266-270.
32. Garber K. Realistic rodents? Debate grows over new mouse models of cancer. JNCI J Natl Cancer Inst 2006, 98:1176-1178.
33. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2007, 2:16. 10.1186/1745-6673-2-16, 2222591, 18053152.
34. Clarke R, Dickson RB, Brunner N. The process of malignant progression in human breast cancer. Ann Oncol 1990, 1:401-407.
35. Sinisterra RD, Shastri VP, Najjar R, Langer R. Encapsulation and release of rhodium(II) citrate and its association complex with hydroxypropyl-beta-cyclodextrin from biodegradable polymer microspheres. J Pharm Sci 1999, 88:574-576. 10.1021/js9804314, 10229652.
36. Laurent S, Bridot JL, Elst LV, Muller RN. Magnetic iron oxide nanoparticles for biomedical applications. Future Med Chem 2:427-449.
37. Choi KY, Liu G, Lee S, Chen X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 4:330-342.
38. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284. 10.1016/S0168-3659(99)00248-5, 10699287.
39. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 624:25-37.
40. Leong H, Marthur PS. Inhibition of mammary tumorigenesis in the C3(1)/SV40 mouse model by green tea. Preclinical study 2008, 107:359-369.
41. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 Breast Tumor Model. Current Protocols in Immunology 2000, John Wiley & Son I.
42. Kwok JC, Richardson DR. The iron metabolism of neoplastic cells: alterations that facilitate proliferation?. Crit Rev Oncol Hematol 2002, 42:65-78. 10.1016/S1040-8428(01)00213-X, 11923069.
43. Ge Y, Zhang Y, Xia J, Ma M, He S, Nie F, Gu N. Effect of surface charge and agglomerate degree of magnetic iron oxide nanoparticles on KB cellular uptake in vitro. Colloids Surf B Biointerfaces 2009, 73:294-301. 10.1016/j.colsurfb.2009.05.031, 19564099.
44. Riviere C, Boudghene FP, Gazeau F, Roger J, Pons JN, Laissy JP, Allaire E, Michel JB, Letourneur D, Deux JF. Iron oxide nanoparticle-labeled rat smooth muscle cells: cardiac MR imaging for cell graft monitoring and quantitation. Radiology 2005, 235:959-967. 10.1148/radiol.2353032057, 15845788.
45. de Freitas ER, Soares PR, Santos Rde P, dos Santos RL, da Silva JR, Porfirio EP, Bao SN, Lima EC, Morais PC, Guillo LA. In vitro biological activities of anionic gamma-Fe2O3 nanoparticles on human melanoma cells. J Nanosci Nanotechnol 2008, 8:2385-2391. 10.1166/jnn.2008.275, 18572653.
46. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003, 24:1001-1011. 10.1016/S0142-9612(02)00440-4, 12504522.
47. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005, 18:374-381. 10.1038/modpathol.3800254, 15578079.
48. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11:486.
49. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000, 18:1423-1431.
50. Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Vujaskovic Z, Satoh T, Baba S, Baust JM, Baust JG, Polascik TJ. Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density. Cryobiology 61:148-154.
51. Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 2009, 8:2872-2881. 10.1158/1535-7163.MCT-09-0583, 2782518, 19825805.
52. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005, 11:3465-3474. 10.1158/1078-0432.CCR-04-1770, 15867249.
53. Ganss R. Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. J Cell Mol Med 2006, 10:857-865. 10.1111/j.1582-4934.2006.tb00530.x, 17125590.
54. Darzynkiewicz Z, Huang X. Analysis of cellular DNA content by flow cytometry. Current protocols in immunology 2004, Coligan JE, Chapter 5:Unit 5 7.
55. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic liposomes: an in vivo study. Jpn J Cancer Res 1998, 89:463-469. 10.1111/j.1349-7006.1998.tb00586.x, 9617354.